Plain-English translation of NCT04504136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand why some people with inflammatory bowel disease (IBD) don't heal well after treatment with anti-TNF therapy, a common biologic medication. By comparing tissue samples from IBD patients starting anti-TNF therapy with samples from people without IBD and people with other conditions also taking anti-TNF therapy, the study will look at how genes and cell energy production differ during the healing process.
Many people with IBD don't respond well to the medication or lose improvement over time, which can lead to serious complications like surgery or cancer. Understanding the basic biology of why healing fails in some patients could help doctors develop better treatments in the future.
If you have IBD, you'll have two endoscopies (a procedure to look inside your intestines) — one as part of your regular care and one scheduled for research. During these procedures, the doctor will take small tissue samples from your intestines. The research team will then study how genes and energy production work in these samples. Participation takes place over a few weeks as you begin your new treatment.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
Terrence A Barrett
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment target
~26 participants
Started
April 2021
Primary completion
August 2024
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in September 2026.